Kodiak Sciences Inc.

Informe acción NasdaqGM:KOD

Capitalización de mercado: US$2.6b

Kodiak Sciences Dividendos y recompras

Dividendo controles de criterios 0/6

Kodiak Sciences no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-7.0%

Rendimiento de la recompra

Rendimiento total para el accionista-7.0%
Rendimiento futuro de los dividendos0%
Crecimiento de los dividendosn/a
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Ratio de pagon/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha
Artículo de análisis • Oct 03

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...
Seeking Alpha • Feb 24

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies. From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels. Read the full article on Seeking Alpha
Artículo de análisis • Dec 13

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 15

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Summary Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies due to unexpected cataract development. Tarcocimab showed superiority over sham and better tolerability in a Phase 3 diabetic retinopathy trial, prompting Kodiak to resurrect the asset and initiate more pivotal trials. My previous recommendation was "sell" due to high risk and limited upside, but recent positive data and clinical advancements warrant a reassessment. KOD merits a "hold" ahead of key developments in their clinical trials, but this isn't for the faint of heart and works best within a barbell portfolio. Read the full article on Seeking Alpha
Artículo de análisis • Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Artículo de análisis • Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Dec 29

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Sep 09

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • May 26

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Jan 04

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Sep 25

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Shares have perked up since announcing the BEACON top line data. We are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve. The following segment was excerpted from this fund letter. Kodiak Sciences (KOD) A great example of companies that can perform in any environment is busted biotech world. One of the sectors undergoing the most pain in the recent year has been biotech, where we have invested in since 2004. Subsequent to the quarter end, we added a second company to our portfolio, and are actively engaged in researching more busted biotechs. Both our newest, Kodiak Sciences (KOD) and MEI Pharma (MEIP) have important regulatory catalysts in the very near future, and they have ample cash to get them through to the value inflection catalyst points. These are the types of names that can perform in any economic environment. The downside is protected by the cash position, and yes, while those cash positions are being spent on funding drug development, the long runways give us ample time to realize these value inflection milestones. We have been buyers of both companies as the market remains relatively indifferent to the looming regulatory updates. Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab (formerly KSI-301), failed its very poorly designed clinical trial. The company’s drug will fill a significant unmet medical need, particular for diabetic and elderly patients with macular edema who have given up going to their doctor every 1-2 months to get their eye injected with Regeneron’s EYLEA. Industry research suggests that well over half of patients have chosen deteriorating vision over the inconvenience of getting their eyes injected every 1-2 months. That’s where tarcocimab comes in. In recent trials, even the “failed” trial, it has shown that 60-70% of patients can go five months or longer while maintaining the same significantly improved vision. While there are multiple therapies available for these patients, there are none that have the durability of tarcocimab. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Tarcocimab seeks to disrupt a $13 billion industry, but more importantly, fill an important gap in the macular edema market. In our conversations with doctors actively engaged in research & clinical trials, they are very eager to have a drug that they can dose less frequently. Shares have perked up since announcing the BEACON top line data, but given they still trade below cash levels, they give us a lot of upside as subsequent trials prove out that the drug works. Given the rest of the pivotal trials will read out in the next nine months, we won’t have to wait long until tarcocimab is able to serve the significant unmet medical need, and file for approval with the FDA next year. We also expect a very important update to MEIP’s regulatory strategy which will alleviate market concerns on its own drug’s timeliness to market. While many catalysts depend on a healthy market environment to play out, these do not. They can perform in any economic scenario. Trying to predict with accuracy when the stock will reflect the underlying developments is impossible. But we do know that if you miss the most material upside days of certain stocks, the realized returns are significantly more mediocre. To the extent we are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve.
Seeking Alpha • Aug 07

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences (NASDAQ:KOD) is scheduled to announce FQ1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$1.75 Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward.
Artículo de análisis • May 18

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 17

Kodiak Sciences: Potential For Comeback After Trial Setback

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023. Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.
Seeking Alpha • Feb 25

Kodiak Sciences: KSI-301 Disappoints

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment Regeneron’s (REGN) Eylea in improvement in visual acuity. The study did not meet the primary endpoint. While KSI-301 appears safe and effective, it may not become a blockbuster.
Seeking Alpha • Feb 15

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of less frequent dosing. The first price target is $90 after positive data from the wet AMD Phase 3 trial this quarter or 70% upside potential in the stock (implied move from the options).
Artículo de análisis • Jan 24

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Oct 11

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. A full investment analysis is presented in the paragraphs below.

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de KOD han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de KOD han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Kodiak Sciences vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de KOD con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (KOD)n/a
Suelo de mercado 25% (US)1.4%
Techo de mercado 25% (US)4.2%
Media de la industria (Biotechs)2.5%
Analista de previsiones (KOD) (hasta 3 años)0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de KOD en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de KOD en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de KOD para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que KOD no ha comunicado ningún pago.

Descubre empresas que pagan buenos dividendos

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/11 01:03
Precio de las acciones al final del día2026/05/11 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Kodiak Sciences Inc. está cubierta por 18 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Anita DushyanthBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Ying HuangBofA Global Research